Diffuse Panbronchiolitis

Shoji Kudoh; Naoto Keicho

doi:10.1055/s-2004-815608

Seminars in Respiratory and Critical Care Medicine, Inhaltsverzeichnis

Semin Respir Crit Care Med 2003; 24(5): 607-618
DOI: 10.1055/s-2004-815608

Diffuse Panbronchiolitis

Shoji Kudoh¹ , Naoto Keicho²

¹Fourth Department of Internal Medicine, Nippon Medical School, Tokyo, Japan
²Department of Respiratory Diseases, Research Institute, International Medical Center of Japan, Toyama, Shinyuku-ku, Tokyo, Japan

Abstract

ABSTRACT

Diffuse panbronchiolitis (DPB) was first distinguished from chronic obstructive pulmonary diseases in the early 1960s and recorded as a new clinicopathologic entity. This disease affects East Asians for the major part, and is characterized by chronic sinobronchial infection together with diffuse bilateral micronodular pulmonary lesions consisting of inflammatory cells. The prognosis at an advanced stage would often be bleak, where superinfection with Pseudomonas aeruginosa had occurred. Beginning with an initial success of erythromycin therapy, considerable improvement has been achieved in the prognosis of this disease. Simple bactericidal activity of macrolides is not a determinant factor for the clinical effect. An in-depth study, together with its pathogenesis, has been performed to clarify the underlying mechanism. Inhibitions of excessive mucus and water secretion from airway epithelium, neutrophil accumulation in the large airway, lymphocyte and macrophage accumulation around the small airway, and modulation of bacterial virulence have so far been proposed as possible mechanisms.

KEYWORDS

Macrolides - chronic airway infection

Volltext

Referenzen

REFERENCES

1 Honma H. Diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1975; 13 383-395
2 Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis [in Japanese]. Naika . 1969; 23 442-451
3 Izumi T, Doi O, Nobechi A. et al .Nation-wide survey of diffuse panbronchiolitis [author's transl] [in Japanese]. Annual Report on the study of interstitial lung disease in 1982. Tokyo:.Grant-in Aid from the Ministry of Health and Welfare of Japan; 1983: 3-41
4 Homma H, Yamanaka A, Tanimoto S. et al . Diffuse panbronchiolitis: a disease of the transitional zone of the lung. Chest . 1983; 83 63-69
5 Kudoh S, Uetake T, Hagiwara K. et al . Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1987; 25 632-642
6 Homma H. Diffuse panbronchiolitis. Jpn J Med . 1986; 25 329-334
7 Kim Y W, Han S K, Shim Y S. et al . The first report of diffuse panbronchiolitis in Korea: five case reports. Intern Med . 1992; 31 695-701
8 Chu Y C, Yeh S Z, Chen C L, Chen C Y, Chang C Y, Chiang C D. Diffuse panbronchiolitis: report of a case. J Formos Med Assoc . 1992; 91 912-915
9 Tredaniel J, Cazals-Hatem D, Zalcman G, d'Agay M F, Capron F. Diffuse panbronchiolitis: efficacy of low-dose erythromycin. Respir Med . 1994; 88 479-480
10 Homer R J, Khoo L, Smith G J. Diffuse panbronchiolitis in a Hispanic man with travel history to Japan. Chest . 1995; 107 1176-1178
11 Hu H, Liu Y, Cai Z, Chen L. A case of diffuse panbronchiolitis. Chin Med J (Engl) . 1996; 109 949-952
12 Zainudin B M, Roslina A M, Fadilah S A, Samad S A, Sufarlan A W, Isa M R. A report of the first three cases of diffuse panbronchiolitis in Malaysia. Med J Malaysia . 1996; 51 136-140
13 Wang H, Sun T, Miao J, Li Y. A definite case of diffuse panbronchiolitis diagnosed by open lung biopsy. Chin Med J (Engl) . 1998; 111 864
14 Tsang K W, Ooi C G, Ip M S. et al . Clinical profiles of Chinese patients with diffuse panbronchiolitis. Thorax . 1998; 53 274-280
15 Poh S C, Wang Y T, Wang W Y. Diffuse panbronchiolitis: a case report. Singapore Med J . 2001; 42 271-274
16 Randhawa P, Hoagland M H, Yousem S A. Diffuse panbronchiolitis in North America: report of three cases and of the literature. Am J Surg Pathol . 1991; 15 43-47
17 Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian male. Sarcoidosis . 1992; 9 67-69
18 Fitzgerald J E, King Jr E T, Lynch D A, Tuder R M, Schwarz M I. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med . 1996; 154(2 Pt 1) 497-503
19 Schulte W, Szrepka A, Bauer P C, Guzman J, Costabel U. Diffuse panbronchiolitis: a rare differential diagnosis of chronic obstructive lung disease [in German]. Dtsch Med Wochenschr . 1999; 124 584-588
20 Chantarotorn S, Palwatwichai A, Vattanathum A, Tantamacharik D. Diffuse panbronchiolitis, the first case reports in Thailand. J Med Assoc Thai . 1999; 82 833-838
21 Gulhan M, Erturk A, Kurt B. et al . Diffuse panbronchiolitis observed in a white man in Turkey. Sarcoidosis Vasc Diffuse Lung Dis . 2000; 17 292-296
22 Claxton S, Markos J. A case of diffuse panbronchiolitis. Aust N Z J Med . 2000; 30 99-100
23 Martinez J A, Guimaraes S M, Ferreira R G, Pereira C A. Diffuse panbronchiolitis in Latin America. Am J Med Sci . 2000; 319 183-185
24 Fisher Jr S M, Rush W L, Rosado-de-Christenson M L. et al . Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent. Arch Pathol Lab Med . 1998; 122 156-160
25 Brugiere O, Milleron B, Antoine M, Carette M F, Philippe C, Mayaud C. Diffuse panbronchiolitis in an Asian immigrant. Thorax . 1996; 51 1065-1067
26 Corne J. Diffuse panbronchiolitis: a new Japanese export?. Lancet . 1996; 348 1465-1466
27 Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis . 1990; 141 1459-1462
28 Keicho N, Tokunaga K, Nakata K. et al . Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am J Respir Crit Care Med . 1998; 158 846-850
29 Park M H, Kim Y W, Yoon H I. et al . Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am J Respir Crit Care Med . 1999; 159 526-529
30 Keicho N, Ohashi J, Tamiya G. et al . Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet . 2000; 66 501-507
31 Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax . 1994; 49 531-532
32 Akai S, Okayama H, Shimura S, Tanno Y, Sasaki H, Takishima T. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis . 1992; 146 781-783
33 Ichikawa Y, Ninomiya H, Koga H. et al . Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis . 1992; 146 196-203
34 Kadota J, Sakito O, Kohno S. et al . A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis . 1993; 147 153-159
35 Yoshimura K, Iizuka S, Anzai C. et al . Diffuse panbronchiolitis is closely associated with mutations of the CFTR gene. Am J Respir Crit Care Med . 2000; 161 A77
36 Sugiyama Y, Kudoh S, Kitamura S. A case of the bare lymphocyte syndrome with clinical manifestations of diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1989; 27 980-983
37 Donato L, de la Salle H, Hanau D. et al . Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J Pediatr . 1995; 127 895-900
38 Teisserenc H, Schmitt W, Blake N. et al . A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunol Lett . 1997; 57 183-187
39 Furukawa H, Murata S, Yabe T. et al . Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest . 1999; 103 755-758
40 Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. J Clin Invest . 1999; 103 595-596
41 Azuma A, Keicho N, Furukawa H, Yabe T, Kudoh S. Prolonged survival of a bare lymphocyte syndrome type I patient with diffuse panbronchiolitis treated with erythromycin. Sarcoidosis Vasc Diffuse Lung Dis . 2001; 18 312-313
42 Maeda M, Saiki S, Yamanaka A. Serial section analysis of the lesions in diffuse panbronchiolitis. Acta Pathol Jpn . 1987; 37 693-704
43 Iwata M, Colby T V, Kitaichi M. Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum Pathol . 1994; 25 357-363
44 Sato A, Chida K, Iwata M, Hayakawa H. Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis. Am Rev Respir Dis . 1992; 146 473-478
45 Mukae H, Kadota J, Kohno S. et al . Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med . 1995; 152 613-618
46 Ichikawa Y, Koga H, Tanaka M, Nakamura M, Tokunaga N, Kaji M. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis. Chest . 1990; 98 917-923
47 Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest . 1994; 106 1116-1123
48 Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest . 1995; 108 116-122
49 Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin-1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration . 1996; 63 42-48
50 Oishi K, Sonoda F, Kobayashi S. et al . Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun . 1994; 62 4145-4152
51 Kusano S, Kadota J, Kohno S. et al . Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration . 1995; 62 217-222
52 Beringer P M. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Curr Opin Pulm Med . 1999; 5 371-377
53 Konstan M W. Therapies aimed at airway inflammation in cystic fibrosis. Clin Chest Med . 1998; 19 505-513
54 Akira M, Kitatani F, Lee Y S. et al . Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology . 1988; 168 433-438
55 Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology . 1992; 184 779-785
56 Hansell D M. Small airways diseases: detection and insights with computed tomography. Eur Respir J . 2001; 17 1294-1313
57 Takizawa H, Tadokoro K, Miyoshi Y. et al . Serological characterization of cold agglutinin in patients with diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1986; 24 257-263
58 Koyama H, Nishimura K, Mio T, Ikeda A, Sugiura N, Izumi T. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis. Thorax . 1994; 49 540-544
59 Nakata K. Revision of clinical guidelines for DPB [author's transl] [in Japanese]. Annual Report on the study of diffuse lung disease in 1998. Tokyo:Grant-in Aid from the Ministry of Health and Welfare of Japan; 1999: 109-111
60 Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections-first report: comparison with amoxicillin [in Japanese]. Kansenshogaku Zasshi . 1986; 60 37-44
61 Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and newquinolone antibacterial agents on diffuse panbronchiolitis [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi . 1990; 28 1305-1313
62 Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration . 1991; 58 145-149
63 Fujii T, Kadota J, Kawakami K. et al . Long-term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax . 1995; 50 1246-1252
64 Yamada G, Igarashi T, Itoh E, Tanaka H, Sekine K, Abe S. Centrilobular nodules correlate with air trapping in diffuse panbronchiolitis during erythromycin therapy. Chest . 2001; 120 198-202
65 Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis: detection by high-resolution computed tomography. Chest . 1995; 107 120-125
66 Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology . 1993; 189 559-562
67 Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long-term chemotherapy with erythromycin in chronic lower respiratory tract infections-second report: including cases with Pseudomonas infections [in Japanese]. Kansenshogaku Zasshi . 1986; 60 45-50
68 Yamamoto M. A double-blind placebo-controlled study on the therapeutic effect of erythromycin on DPB [author's transl.] [in Japanese]. Annual Report on the study of diffuse lung disease in 1990 [in Japanese] Tokyo: Grant-in Aid from the Ministry of Health and Welfare of Japan 1991: 18-20
69 Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med . 1998; 157(6 Pt 1) 1829-1832
70 Nakamura H, Fujishima S, Inoue T. et al . Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J . 1999; 13 1371-1379
71 Mikasa K, Sawaki M, Kita E. et al . Long-term chemotherapy using erythromycin (EM) for chronic lower airway infection: effectiveness of clarithromycin in EM ineffective cases-the fourth report [in Japanese]. Kansenshogaku Zasshi . 1992; 66 1097-10104
72 Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother . 1995; 39 1688-1690
73 Shirai T, Sato A, Chida K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern Med . 1995; 34 469-474
74 Nakata K, Taguchi Y, Kudoh S. Therapeutic guidelines for DPB [author's transl.] [in Japanese]. Annual Report on the study of diffuse lung disease in 1999. Tokyo: Grant-in Aid from the Ministry of Health and Welfare of Japan; 2000: 111
75 Kudoh S. Erythromycin treatment in diffuse panbronchiolitis. Curr Opin Pulm Med . 1998; 4 116-121
76 Koyama H, Geddes D M. Erythromycin and diffuse panbronchiolitis. Thorax . 1997; 52 915-918
77 Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol . 2001; 31 464-473
78 Rubin B K, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs . 2000; 1 169-172
79 Kadota J. Antiinflammatory effects of macrolide therapy in patients with diffuse panbronchiolitis, a chronic inflammatory airway disease. Recent Res Devel Antimicrob Agents & Chemother . 1999; 3(Pt 1) 17-38
80 Wales D, Woodhead M. The anti-inflammatory effects of macrolides. Thorax . 1999; 54 (suppl 2) S58-S62
81 Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis: pathophysiology and treatment mechanisms. Int J Antimicrob Agents . 2001; 18 (suppl 1) S83-S87
82 Labro M T. Anti-inflammatory activity of macrolides: a new therapeutic potential?. J Antimicrob Chemother . 1998; 41 (suppl B) S37-S46
83 Hoyt J C, Robbins R A. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett . 2001; 205 1-7
84 Culic O, Erakovic V, Parnham M J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol . 2001; 429 209-229
85 Azuma A. Novel activity of erythromycin derivatives on inflammatory lung diseases. Recent Res Devel Respir Crit Care Med . 2001; 1 191-207
86 Rubin B K, Druce H, Ramirez O E, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med . 1997; 155 2018-2123
87 Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J . 1992; 5 234-238
88 Kondo M, Kanoh S, Tamaoki J, Shirakawa H, Miyazaki S, Nagai A. Erythromycin inhibits ATP-induced intracellular calcium responses in bovine tracheal epithelial cells. Am J Respir Cell Mol Biol . 1998; 19 799-804
89 Zhao D M, Xue H H, Chida K. et al . Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol . 2000; 278 L726-736
90 Hojo M, Fujita I, Hamasaki Y, Miyazaki M, Miyazaki S. Erythromycin does not directly affect neutrophil functions. Chest . 1994; 105 520-523
91 Mitsuyama T, Hidaka K, Furuno T, Hara N. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol . 1997; 114 111-115
92 Takizawa H, Desaki M, Ohtoshi T. et al . Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am J Respir Crit Care Med . 1997; 156 266-271
93 Desaki M, Takizawa H, Ohtoshi T. et al . Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun . 2000; 267 124-128
94 Aoki Y, Kao P N. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother . 1999; 43 2678-2684
95 Abe S, Nakamura H, Inoue S. et al . Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol . 2000; 22 51-60
96 Khair O A, Devalia J L, Abdelaziz M M, Sapsford R J, Davies R J. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J . 1995; 8 1451-1457
97 Keicho N, Kudoh S, Yotsumoto H, Akagawa K S. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (Tokyo) . 1993; 46 1406-1413
98 Morikawa K, Oseko F, Morikawa S, Iwamoto K. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. Antimicrob Agents Chemother . 1994; 38 2643-2647
99 Kita E, Sawaki M, Nishikawa F. et al . Enhanced interleukin production after long-term administration of erythromycin stearate. Pharmacology . 1990; 41 177-183
100 Sugiyama Y, Yanagisawa K, Tominaga S I, Kitamura S. Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur Respir J . 1999; 14 1113-1116
101 Tamaoki J, Kondo M, Kohri K, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics protect against immune complex-induced lung injury in rats: role of nitric oxide from alveolar macrophages. J Immunol . 1999; 163 2909-2915
102 Keicho N, Kudoh S, Yotsumoto H, Akagawa K S. Erythromycin promotes monocyte to macrophage differentiation. J Antibiot (Tokyo) . 1994; 47 80-89
103 Howe R A, Spencer R C. Macrolides for the treatment of Pseudomonas aeruginosa infections?. J Antimicrob Chemother . 1997; 40 153-155
104 Kita E, Sawaki M, Oku D. et al . Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J Antimicrob Chemother . 1991; 27 273-284
105 Sakata K, Yajima H, Tanaka K. et al . Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am Rev Respir Dis . 1993; 148(4 Pt 1) 1061-1065
106 Molinari G, Guzman C A, Pesce A, Schito G C. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother . 1993; 31 681-688
107 Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med . 1995; 99(6A) 26S-30S
108 Davies D G, Parsek M R, Pearson J P, Iglewski B H, Costerton J W, Greenberg E P. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science . 1998; 280 295-298
109 Tateda K, Comte R, Pechere J C, Kohler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa Antimicrob Agents Chemother . 2001; 45 1930-1933